Therapeutic RNA aptamers in clinical trials

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 259-271

  Sundaram, Padma ^a,b   Kurniawan, Helena ^a,b   Byrne, Mark E ^a   Wower, Jacek ^b  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Aptamer; Clinical trials; RNA; Therapeutics

Indexed keywords

ANIVAMERSEN; ANTINEOPLASTIC AGENT; APTAMER; ARC 1905; ARC 19499; AS 1411; E 10030; EGAPTIVON PEGOL; FOVISTA; NOX A 12; NOX E 36; NU 172; PEGAPTANIB; PEGNIVACOGIN; RANIBIZUMAB; RNA APTAMER; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ANGIOMA; CORONARY ARTERY DISEASE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; FOOD AND DRUG ADMINISTRATION; HEMOPHILIA; HUMAN; KIDNEY CARCINOMA; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; LUPUS ERYTHEMATOSUS NEPHRITIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON HIPPEL LINDAU DISEASE; VON WILLEBRAND DISEASE;

ANIMALS; APTAMERS, NUCLEOTIDE; DIABETES MELLITUS, TYPE 2; HEMOSTASIS; HUMANS; MACULAR DEGENERATION; NEOPLASMS;

EID: 84870680921     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.10.014     Document Type: Review

References (112)

1. P.J. Bates, D.A. Laber, D.M. Miller, S.D. Thomas, and J.O. Trent Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer Exp. Mol. Pathol. 86 2009 151 164
2. L. Beigelman, J. Matulic-Adamic, P. Haeberli, N. Usman, B. Dong, R.H. Silverman, S. Khamnei, and P.F. Torrence Synthesis and biological activities of a phosphorodithioate analog of 2′, 5′-oligoadenylate Nucleic Acids Res. 23 1995 3989 3994
3. A. Bendele, J. Seely, C. Richey, G. Sennello, and G. Shopp Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins Toxicol. Sci. 42 1998 152 157
4. M. Berezovski, A. Drabovich, and S.M. Krylova Nonequilibrium capillary electrophoresis of equilibrium mixtures: a universal tool for development of aptamers J. Am. Chem. Soc. 127 9 2005 3165 3171
5. P.R. Bouchard, R.M. Hutabarat, and K.M. Thompson Discovery and development of therapeutic aptamers Annu. Rev. Pharmacol. Toxicol. 50 2010 237 257
6. E.N. Brody, and L. Gold Aptamers as therapeutic and diagnostic agents Rev. Mol. Biotechnol. 74 2000 5 13
7. P. Burgstaller, and M. Famulok Isolation of RNA aptamers for biological cofactors by in vitro selection Angew. Chem.; Int. Ed. Engl. 33 1994 1084 1087
8. P.E. Burmeister, S.D. Lewis, R.F. Silva, J.R. Preiss, L.R. Horwitz, P.S. Pendergrast, T.G. McCauley, J.C. Kurz, D.M. Epstein, C. Wilson, and A.D. Keefe Direct in vitro selection of a 2′-O-methyl aptamer to VEGF Chem. Biol. 12 2005 25 33
9. L. Cerchia, F. Ducongé, C. Pestourie, J. Boulay, Y. Aissouni, K. Gombert, B. Tavitian, V.d. Franciscis, and D. Libri Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase PLoS Biol. 3 2005 697 704
10. L. Cerchia, P.H. Giangrande, J.O. McNamara, and V. de Franciscis Cell-specific aptamers for targeted therapies Methods Mol. Biol. 78 535 2009 559
11. M.Y. Chan, M.G. Cohen, C.K. Dyke, S.K. Myles, L.G. Aberle, M. Lin, J. Walder, S.R. Steinhubl, I.C. Gilchrist, N.S. Kleiman, D.A. Vorchheimer, N. Chronos, C. Melloni, J.H. Alexander, R.A. Harrington, R.M. Tonkens, R.C. Becker, and C.P. Rusconi Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease Circulation 117 2008 2865 2874
12. M.Y. Chan, C.P. Rusconi, J.H. Alexander, R.M. Tonkens, R.A. Harrington, and R.C. Becker A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor J. Thromb. Haemost. 6 2008 789 796
13. J. Chelliserrykattil, and A.D. Ellington Evolution of a T7 RNA polymerase variant that transcribes 2[prime]-O-methyl RNA Nat. Biotech. 22 2004 1155 1160
14. C.-h.B. Chen, G.A. Chernis, V.Q. Hoang, and R. Landgraf Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 Proc. Nat. Acad. Sci. 100 2003 9226 9231
15. M.G. Cohen, D.A. Purdy, J.S. Rossi, L.R. Grinfeld, S.K. Myles, L.H. Aberle, A.B. Greenbaum, E. Fry, M.Y. Chan, R.M. Tonkens, S. Zelenkofske, J.H. Alexander, R.A. Harrington, C.P. Rusconi, and R.C. Becker First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention/CLINICAL PERSPECTIVE Circulation 122 2010 614 622
16. J.C. Cox, and A.D. Ellington Automated selection of anti-Protein aptamers Bioorg. Med. Chem. 9 2001 2525 2531
17. D.A. Daniels, H. Chen, B.J. Hicke, K.M. Swiderek, and L. Gold A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment Proc. Nat. Acad. Sci. 100 2003 15416 15421
18. A.P. Drabovich, M. Berezovski, V. Okhonin, and S.N. Krylov Selection of smart aptamers by methods of kinetic capillary electrophoresis Anal. Chem. 78 9 2006 3171 3178
19. C.K. Dyke, S.R. Steinhubl, N.S. Kleiman, R.O. Cannon, L.G. Aberle, M. Lin, S.K. Myles, C. Melloni, R.A. Harrington, J.H. Alexander, R.C. Becker, and C.P. Rusconi First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology Circulation 114 2006 2490 2497
20. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
21. D. Eulberg, K. Buchner, C. Maasch, and S. Klussmann Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist Nucleic Acids Res. 33 2005 e45
22. D. Eulberg, and S. Klussmann Spiegelmers: biostable aptamers ChemBioChem 4 2003 979 983
23. M. Famulok, and A. Jenne Oligonucleotide libraries-variatio delectat Curr. Opin. Chem. Biol. 2 1998 320 327
24. M. Famulok, and G. Mayer Aptamers as tools in molecular biology and immunology Curr. Top. Microbiol. Immunol. 243 1999 123 136
25. C.A. Farman, and D.J. Kornbrust Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications Toxicol. Pathol. 31 2003 119 122
26. Friberg, T.R.; Tolentino, M.; Group, f.t.L.S.; 2010. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Brit. J. Ophthalmol.
27. G.E. Gilbert, and A.E. Mast Curbing an inhibitor for hemostasis Blood 117 2011 5277 5278
28. J.C. Gilbert, T. DeFeo-Fraulini, R.M. Hutabarat, C.J. Horvath, P.G. Merlino, H.N. Marsh, J.M. Healy, S. BouFakhreddine, T.V. Holohan, and R.G. Schaub First-in-human evaluation of anti-von willebrand factor therapeutic aptamer ARC1779 in healthy volunteers Circulation 116 2007 2678 2686
29. A.C. Girvan, Y. Teng, L.K. Casson, S.D. Thomas, S. Jüliger, M.W. Ball, J.B. Klein, W.M. Pierce, S.S. Barve, and P.J. Bates AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin Mol. Cancer Ther. 5 2006 1790 1799
30. Gold, L.; Janjic, N.; Jarvis, T.; Schneider, D.; Walker, J.J.; Wilcox, S.K.; Zichi, D.; 2010. Aptamers and the RNA world, past and present. Cold Spring Harbor Perspect. Biol.
31. L. Gold, B. Polisky, O. Uhlenbeck, and M. Yarus Diversity of oligonucleotide functions Annu. Rev. Biochem. 64 1995 763 797
32. V.H. González, G.P. Giuliari, R.M. Banda, and D.A. Guel Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy Br. J. Ophthalmol. 93 2009 1474 1478
33. L. Griffin, G. Tidmarsh, L. Bock, J. Toole, and L. Leung In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits Blood 81 1993 3271 3276
34. M.D.R.S. Group A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 112 2005 1747 1757
35. S.P. Hale, and P. Schimmel Protein synthesis editing by a DNA aptamer Proc. Nat. Acad. Sci. 93 1996 2755 2758
36. J.M. Healy, S.D. Lewis, M. Kurz, R.M. Boomer, K.M. Thompson, C. Wilson, and T.G. McCauley Pharmacokinetics and biodistribution of novel aptamer compositions Pharm. Res. 21 2004 2234 2246
37. S.P. Henry, P.C. Giclas, J. Leeds, M. Pangburn, C. Auletta, A.A. Levin, and D.J. Kornbrust Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action J. Pharmacol. Exp. Ther. 281 1997 810 816
38. S.P. Henry, T.W. Kim, K.K. Stickland, T.A. Zanardi, R.A. Fey, and A.A. Levin Toxicological Properties of 2'-O-Methyoxyethyl Chimeric Antisense Inhibitors in Animal and Man second ed. 2008 Taylor and Francis Boca Raton, FL
39. T. Hermann, and D.J. Patel Adaptive recognition by nucleic acid aptamers Science 287 2000 820 825
40. J. Hesselberth, M.P. Robertson, S. Jhaveri, and A.D. Ellington In vitro selection of nucleic acids for diagnostic applications Rev. Mol. Biotechnol. 74 2000 15 25
41. Y. Huang, F. Eckstein, R. Padilla, and R. Sousa Mechanism of ribose 2'-group discrimination by an RNA polymerase† Biochemistry 36 1997 8231 8242
42. C.R. Ireson, and L.R. Kelland Discovery and development of anticancer aptamers Mol. Cancer Ther. 5 2006 2957 2962
43. D. Jellinek, L.S. Green, C. Bell, and N. Janjic Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor Biochemistry 33 1994 10450 10456
44. B. Jilma, P. Paulinska, P. Jilma-Stohlawetz, J.C. Gilbert, R. Hutabarat, and P. Knöb A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease Thromb. Haemost. 104 2010 563 570
45. N. Jo, C. Mailhos, M. Ju, E. Cheung, J. Bradley, K. Nishijima, G.S. Robinson, A.P. Adamis, and D.T. Shima Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization Am. J. Pathol. 168 2006 2036 2053
46. A.D. Keefe, and S.T. Cload SELEX with modified nucleotides Curr. Opin. Chem. Biol. 12 2008 448 456
47. A.D. Keefe, S. Pai, and A. Ellington Aptamers as therapeutics Nat. Rev. Drug Discov. 9 2010 537 550
48. D. Kiga, Y. Futamura, K. Sakamoto, and S. Yokoyama An RNA aptamer to the xanthine/guanine base with a distinctive mode of purine recognition Nucleic Acids Res. 26 1998 1755 1760
49. S. Klussmann, A. Nolte, R. Bald, V.D. Erdmann, and J.P. Furste Mirror image RNAthat binds D-adenosine Nat. Biotechnol. 14 1996 1112 1115
50. D.A. Laber, M.A. Choudry, B.S. Taft, L. Bhupalam, V.R. Sharma, F.J. Hendler, and K.M. Barnhart A phase I study of AGRO100 in advanced cancer ASCO Meet. Abstr. 22 2004 3112
51. D.A. Laber, V.R. Sharma, L. Bhupalam, B. Taft, F.J. Hendler, and K.M. Barnhart Update on the first phase I study of AGRO100 in advanced cancer ASCO Meet. Abstr. 23 2005 3064
52. D.A. Laber, B.S. Taft, G.H. Kloecker, P.J. Bates, J.O. Trent, and D.M. Miller Extended phase I study of AS1411 in renal and non-small cell lung cancers ASCO Meet. Abstr. 24 2006 13098
53. D. Li, L. Chen, and X. Wu Aptamer against IL-17RA from CELL-SELEX as a new adjunctive therapeutic reagent delayed inflammatory processes with the inhibition of IL-6 in murine experimental osteoarthritis Acta Biochim. Biophys. Sin. 42 1 2010 19 66
54. C. Lin, E. Katilius, Y. Liu, J. Zhang, and H. Yan Self-assembled signaling aptamer DNA arrays for protein detection Angew. Chem. 118 2006 5422 5427
55. J. Liu, Y. Yang, B. Hu, Z. Ma, H.P. Huang, Y. Yu, S.P. Liu, M.J. Lu, and D.L. Yu Development of HBsAg-binding aptamers that bind HepG2.2.15 cells via HBV surface antigen Virol. Sin. 25 2010 27 35
56. D.K. Monteith, M.J. Horner, N.A. Gillett, M. Butler, R. Geary, T. Burckin, T. Ushiro-Watanabe, and A.A. Levin Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys Toxicol. Pathol. 27 1999 307 317
57. R.K. Mosing, and M.T. Bowser Isolating aptamer using capillary electrophoresis-SELEX (CE-SELEX) Methods Mol. Biol. 535 1 2009 33 43
58. E.W.M. Ng, and A.P. Adamis Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases Ann. N. Y. Acad. Sci. 1082 2006 151 171
59. E.W.M. Ng, D.T. Shima, P. Calias, E.T. Cunningham Jr, D.R. Guyer, and A.P. Adamis Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat. Rev. Drug Discovery 5 2006 123 132
60. S.M. Nimjee, C.P. Rusconi, R.A. Harrington, and B.A. Sullenger The potential of aptamers as anticoagulants Trends Cardiovasc. Med. 15 2005 41 45
61. K. Nishijima, Y.-S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S.J. Samuelsson, G.S. Robinson, A.P. Adamis, and D.T. Shima Vascular endothelial growth factor-a is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am. J. Pathol. 171 2007 53 67
62. D.J. Patel Structural analysis of nucleic acid aptamers Curr. Opin. Chem. Biol. 1 1997 32 46
63. D.J. Patel, and A.K. Suri Structure, recognition and discrimination in RNA aptamer complexes with cofactors, amino acids, drugs and aminoglycoside antibiotics Rev. Mol. Biotechnol. 74 2000 39 60
64. T.J. Povsic, W.A. Wargin, J.H. Alexander, J. Krasnow, M. Krolick, M.G. Cohen, R. Mehran, C.E. Buller, C. Bode, S.L. Zelenkofske, C.P. Rusconi, R.C. Becker, and o.b.o.t.R. Investigators Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy Eur. Heart J. 32 2011 2412 2419
65. P. Ray, and R.R. White Aptamers for targeted drug delivery Pharmaceuticals 3 2010 1761 1778
66. D. Ricklin, and J.D. Lambris Complement-targeted therapeutics Nat. Biotech. 25 2007 1265 1275
67. D. Rizzieri, K. Stockerl-Goldstein, A. Wei, R.H. Herzig, F. Erlandsson, and R.K. Stuart Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML ASCO Meet. Abstr. 28 2010 6557
68. D.E. Robertson, and G.F. Joyce Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA Nature 334 1990 467 468
69. J.E. Rosenberg, H.A. Drabkin, P. Lara, A.L. Harzstark, R.A. Figlin, G.W. Smith, F. Erlandsson, and D.A. Laber A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC) ASCO Meet. Abstr. 28 2010 4590
70. M. Saint-Geniez, T. Kurihara, E. Sekiyama, A.E. Maldonado, and P.A. D'Amore An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris Proc. Nat. Acad. Sci. 106 2009 18751 18756
71. K.S. Schmidt, S. Borkowski, J. Kurreck, A.W. Stephens, R. Bald, M. Hecht, M. Friebe, L. Dinkelborg, and V.A. Erdmann Application of locked nucleic acids to improve aptamer in vivo stability and targeting function Nucleic Acids Res. 32 2004 5757 5765
72. S.M. Shamah, J.M. Healy, and S.T. Cload Complex target SELEX Acc. Chem. Res. 41 2008 130 138
73. J.P. Sheehan, and H.-C. Lan Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex Blood 92 1998 1617 1625
74. S. Soundararajan, W. Chen, E.K. Spicer, N. Courtenay-Luck, and D.J. Fernandes The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells Cancer Res. 68 2008 2358 2365
75. Stuart, R.K.; Wei, A.; Lewis, I.D.; Estey, E.; Erlandsson, F.; Schiller, G.J.; 2010. A multicenter dose-finding randomized controlled phase IIb study of the aptamer AS1411 in patients with primary refractory or relapsed AML. ASCO, Meet. Abstr. 28, TPS279.
76. B.A. Sullenger, H.F. Gallardo, G.E. Ungers, and E. Gilboa Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication Cell 63 1990 601 608
77. M.B. Sultan, D. Zhou, J. Loftus, T. Dombi, and K.S. Ice A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema Ophthalmology 118 2011 1107 1118
78. J. Tok, J. Lai, T. Leung, and S.F. Yau Li Selection of aptamer for signal transduction protein by capillary electyrophoresis Electrophoresis 31 2010 2055 2062
79. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
80. J.P. Vavalle, C.P. Rusconi, S. Zelenkofske, W.A. Wargin, J.A. Alexander, and R.C. Becker A Phase 1 ascending dose study of subcutaneously administrated factor IXa inhibitor and its active control agent J. Thromb. Haemost. 10 2012 1303 1311
81. Y. Wang, and R.R. Rando Specific binding of aminoglycoside antibiotics to RNA Chem. Biol. 2 1995 281 290
82. E. Waters, J. Richardson, R. Schaub, and J. Kurz Effect of NU172 and bivalirudin on ecarin clotting time in human plasma and whole blood-Posters J. Thromb. Haemost. 7 2009 367
83. E.K. Waters, R.M. Genga, M.C. Schwartz, J.A. Nelson, R.G. Schaub, K.A. Olson, J.C. Kurz, and K.E. McGinness Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor Blood 117 2011 5514 5522
84. B. Wlotzka, S. Leva, B. Eschgfaller, J. Burmeister, F. Kleinjung, C. Kaduk, P. Muhn, H. Hess-Stumpp, and S. Klausmann In vivo properties of an anti-G-nRH Speigelmer: An example of an oligonucleotide based therapeutic substance class Proc. Natt. Acad. Sci. USA 99 2002 8898 8902
85. M.A. Zarbin, and P.J. Rosenfeld Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives Retina 30 2010 1350 1367 doi:1310.1097/IAE.1350b1013e3181f1357e1330
86. J. Zhou, M.R. Battig, and Y. Wang Aptamer based molecular recognition for biosensor recognition Anal. Bioanal. Chem. 398 6 2010 2471 2480
87. J. Zhou, and J.J. Rossi Cell-specific aptamer-mediated targeted drug delivery Oligonucleotides 21 2011 1 10
88. Eyetech Inc.; 2010. Phase 3 Study Presented at World Ophthalmology Congress Evaluates Investigational Use of Macugen in Patients with Diabetic Macular Edema. < http://www.marketwire.com/press-release/phase-3-study- presented-world-ophthalmology-congress-evaluates-investigational-use-macugen- 1271620.htm > (accessed 08.07.12).
89. Fierce Healthcare, 2008. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172. < http://www.fiercehealthcare.com/press-releases/ nuvelo-announces-positive-proof-concept-data-anticogulant-nu172 > (accessed 09.06.12).
90. Genetic Engineering & Biotechnology News (GEN), 2012a. Redefining Oligonucleotid Production. < http://www.genengnews.com/gen-articles/ redefining-oligonucleotide-production/4065/ > (accessed 20.09.12).
91. Genetic Engineering & Biotechnology News (GEN), 2012b. Solid-Phase Support for Oligo Synthesis. < http://www.genengnews.com/gen-articles/solid- phase-supports-for-oligo-synthesis/4096/ > (accessed 20.09.12).
92. NIH, 2006. A Pilot Study for the Treatment of Iris Neovascularization With Macugen. < http://clinicaltrials.gov/ct2/show/NCT00295828?term= macugen&rank=10 > (accessed 03.07.12).
93. NIH, 2008a. Pegaptanib Therapy in Uveitis. < http://clinicaltrials. gov/ct2/show/NCT00790803?term=macugen&rank=15 > (accessed 16.06.12).
94. NIH, 2008b. Long-Term Use of Pegaptanib in Patients for Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. < http://clinicaltrials.gov/ct2/show/NCT00845273?term=macugen&rank=20 > (accessed 16.06.12).
95. NIH, 2009a. NOX-A12 First-in-Human (FIH) Study. < http://www. clinicaltrials.gov/ct2/show/NCT00976378 > (accessed 04.01.12).
96. NIH, 2009b, NOX-E36 First-in-Human (FIH) Study. < http://www. clinicaltrials.gov/ct2/show/NCT00976729 > (accessed 04.01.12).
97. NIH, 2010a. Intravitreal Macugen for Ischaemic Diabetic Macular Oedema (MIDME). < http://clinicaltrials.gov/ct2/show/NCT01175070?term= macugen&rank=2 > (accessed 16.06.12).
98. NIH, 2010b. First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients. < http://clinicaltrials.gov/ct2/show/ NCT01191372 > (accessed 04.01.12).
99. NIH, 2010c. Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia. < http://clinicaltrials. gov/ct2/show/NCT01218230?term=macugen&rank=18 > (accessed 03.07.12).
100. Noxxon Pharma, Spiegelmer® NOX-E36. < http://www.noxxon.com/index. php?option=com-content&view=article&id=60&Itemid=98 > (accessed 03.07.12).
101. Noxxon Pharma, 2009. Noxxon Announces Initiation of First Clinical Trial with a Spiegelmer®. < http://www.noxxon.com/downloads/pressrel/090608- NOXXON-Announces-Initiation-of-First-Clinical-Trial-with-a-Spiegelmer.pdf > (accessed 04.07.12).
102. Noxxon Pharma, 2010a. NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer® NOX-A12. < http://www.noxxon.com/downloads/pressrel/100503-NOXXON-Announces-the-Completion- of-the-First-in-Human-Clinical-Trial-with-Spiegelmer-NOX-A-12.pdf > (accessed 04.07.12).
103. Noxxon Pharma, 2010b. Noxxon Initiates Multiple Dose Phase I Clinical Trail of SDF-1inhibitor NOX-A12. < http://www.noxxon.com/downloads/pressrel/ 2010-09-22-NOXXON-INITIATE-MULTIPLE-DOSE-PHASE-I-CLINICAL-TRIAL-OF-SDF-1- INHIBITOR-NOX-A12.pdf > (accessed 03.07.12).
104. Noxxon Pharma, 2010c. NOXXON to Initiate Phase Ib Clinical Trail of MCP-1 Inhibitor NOX-E36: Study to Include Healthy Volunteers and Diabetic Patients. < http://www.noxxon.com/downloads/pressrel/100707-NOXXON-TO-INITIATE-PHASE- Ib-CLINICAL-TRIAL-OF-MCP-1-INHIBITOR-NOX-E36.pdf > (accessed 04.07.12).
105. Noxxon Pharma, 2011. Noxxon's SDF-1 Inhibitor NOX-A12 Completes Phase I: PRECLINICAL DATA in Models of Hematological Tumors to be Presented at ASH Conference. < http://www.noxxon.com/downloads/pressrel/2011-12-12-NOXXONs- SDF-1-inhibitor-NOX-A12-completes-Phase-I.pdf > (accessed 05.07.12).
106. Noxxon Pharma, 2012. NOXXON Initiates Phase IIa of Anti-CCL2/MCP-1 Spiegelmer® NOX-E36 for Treatment of Diabetic Nephropathy. < http://www.noxxon.com/downloads/pressrel/2012-06-19-NOXXON-Initiates-Phase-IIa- of-Spiegelmer-NOX-E36.pdf > (accessed 03.07.12).
107. Ophthotech, 2012a. Fovista™ (E10030)-Anti-PDGF. < http://www.ophthotech.com/products/e10030/ > (accessed 05.07.12).
108. Ophthotech, 2012b. Ophthotech's Novel Anti-PDGF Combination Agent Fovista™ Demonstrated Superior Efficacy over Lucentis® Monotherapy in Large Controlled Wet AMD Trial. < http://www.ophthotech.com/ophthotechs-anti- pdgf-fovista-superior-efficacy-phase2b/ > (accessed 03.07.12).
109. Retina Today Archive, 2009a Neovascular Regression and Improved Visual Acuity Achieved With Combined Anti-PDGF/Anti-VEGF Therapy. < http://bmctoday.net/retinatoday/2009/06/article.asp?f=0609NEWS-01.php > (accessed 03.07.12).
110. Retina Today Archive, Cousins SW, 2009b. Intravitreal Anti-VEGF and Anti-PDGF Combination Therapy. < http://bmctoday.net/retinatoday/2009/10/ article.asp?f=1009-12.php > (accessed 05.07.12).
111. The Ellington Lab, 2004. Aptamer Database. < http://aptamer.icmb. utexas.edu/index.php > (accessed 23.09.12).
112. Wikinivest, 2009. NUVO NU172. < http://www.wikinvest.com/stock/Nuvelo- %28NUVO%29/Nu172 > (accessed 05.07.12).